top of page
Topic: Central Nervous System tumours
CPGs graded Strong
Weller M et al. (2014). S2k Guidelines for Diagnostics and Therapy in Neurology: Gliomas. AWMF registration number: 030/099. Published by the Guidelines Commission of the German Society of Neurology. Update 2017; 
https://www.dgn.org/images/red_leitlinien/LL_2014/PDFs_Download/030099_DGN_LL_Gliome_final.pdf
​
Hofer S, Bullinger L, Dierlamm J, Grosu AL. (2017). Leitlinie Gliome im Erwachsenenalter (ICD-10 C71); Update 2019.
https://www.onkopedia.com/de/onkopedia/guidelines/gliome-im-erwachsenenalter/@@view/pdf/index.pdf
​
Perrot E, Martin E, Fournel P (2018) on behalf of the editing committee of Auvergne-Rhône-Alpes Guidelines in Thoracic Oncology. [Guidelines on Brain Metastasis of Lung Cancers: 2019 Update]. ARISTOT; 2019 [French]. ISBN 978-2-490858-05-7. Available from http://espacecancer.sante-ra.fr/Pages/referentiels.aspx and from www.lecancer.fr; http://reseau-cancerologie-grand-est.fr/wp-content/uploads/2019/03/M_SNC_2019_VDEF.pdf
​
NICE guideline: Brain tumours (primary) and brain metastases in adults (NG99). Published: 11 July 2018; 
https://www.nice.org.uk/guidance/ng99/resources/brain-tumours-primary-and-brain-metastases-in-adults-pdf-1837763558341
​
Stupp, R., et al. (2014). "High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up." Annals of Oncology 25(suppl_3): iii93-iii101. https://academic.oup.com/annonc/article-pdf/25/suppl_3/iii93/6674203/mdu050.pdf
    
Le Rhun, E., et al. (2017). "EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours." Annals of Oncology 28(suppl_4): iv84-iv99.
https://academic.oup.com/annonc/article-pdf/28/suppl_4/iv84/18564046/mdx221.pdf
​
Weller, M., et al. (2017). "European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas." The Lancet Oncology 18(6): e315-e329. DOI: https://doi.org/10.1016/S1470-2045(17)30194-8; https://www.zora.uzh.ch/id/eprint/141088/1/LO_EANO_2016-9-11.pdf
​
Raverot G, Burman P et al. (2018). European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. European journal of endocrinology 178(1). p.1-24; DOI: https://doi.org/10.1530/EJE-17-0796; 
https://eje.bioscientifica.com/downloadpdf/journals/eje/178/1/EJE-17-0796.xml
​
Rudà, R., et al. (2017). "EANO guidelines for the diagnosis and treatment of ependymal tumors." Neuro-Oncology 20(4): 445-456. 
https://academic.oup.com/neuro-oncology/article-pdf/20/4/445/24688019/nox166.pdf
​
Hoang-Xuan K, Bessell E, Weller M et al. (2015). Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. Lancet Oncology, 16(7):e322-332.
https://www.zora.uzh.ch/id/eprint/114449/1/THELANCETONCOLOGY-D-14-01617R21.pdf
​
CPGs graded Moderate
Soffietti, R., et al. (2017). "Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO)." Neuro-Oncology 19(2): 162-174; doi:10.1093/neuonc/now241. 
 https://doi.org/10.1093/neuonc/now241; https://academic.oup.com/neuro-oncology/article-pdf/19/2/162/17682210/now241.pdf
​
Lancashire and South Cumbria Cancer Network: Management Guidelines for Malignant Brain Tumours. (Version 2, Dated October 2015) review date October 2017;
https://www.gmecscn.nhs.uk/attachments/article/276/LSCCN%20Brain%20Tumour%20GUIDELINES%20Final%20(2).pdf
​
London Cancer Alliance 2014:  Brain/CNS Cancer Clinical Guidelines; 
http://www.londoncanceralliance.nhs.uk/media/74514/LCA_BCNS_Guidelines_FINAL.pdf
​
Burcheri et al. (2013). Lymphomes Cérébraux Primitifs (Recommandations nationales de bonnes pratiques)/ Primary central nervous system lymphomas (PCNSL). Référentiel régional Onco-LR, Comité Onco-Hématologie. 
http://www.oncolr.org/upload/Espace_professionnel/Recommandations_regionales/Validation_lymphomes_cerebraux.pdf
​
​
Schlegel U, Illerhaus G et al. (2015). Primäre ZNS-Lymphome (PZNSL). S2k-Leitlinien für Diagnostik und Therapie in der Neurologie (AWMF-Registernummer: 030/059). 
https://www.awmf.org/uploads/tx_szleitlinien/030-059l_Prim%C3%A4re_ZNS_Lymphome_PZNSL_2015-06-abgelaufen.pdf
​
Rutkowsk S, Trollmann R et al. (2016). S1-Leitlinie 025/022: Leitsymptome und Diagnostik der ZNS-Tumoren im Kindes- und Jugendalter (Tumors of the Central Nervous System in Children and Adolescents).
https://www.awmf.org/uploads/tx_szleitlinien/025-022l_S1_ZNS-Tumoren_Kinder_Jugendliche_2016-09.pdf
​
Unbenannt.JPG

Work Package 6

_project_management_standards.jpg

Tasks of work package 6

​

  • Map available clinical practice guidelines (CPGs) at the European level on all families of rare cancers and identify gaps

  • Quality evaluation of existing guidelines for rare cancer subtypes  

​

The JARC Work Package 6 maintains this website to share the results of quality evaluation of existing CPGs at European local and national level on rare cancers with partners involved in the EU JARC Project. However, the JARC Work Package 6 does not accept any responsibility or obligation of any kind whatsoever with regard to the information contained on this site.

The  JARC WP 6 Website contains links to other websites.

Not having control over the content of these third-party websites, no responsibility is assumed for their policies or practices.

Therefore, please review the privacy policies of these third-party websites.

Tasks of work package 6

​​

  • Open issues about implementation of CPGs at the local level and their interface with reimbursement systems

  • Work out solutions on how to assess the implementation of CPGs in the context of ERNs and national clinical collaborative networks

bottom of page